Kissei Pharmaceutical Co., Ltd.

23 articles about Kissei Pharmaceutical Co., Ltd.

• ObsEva Announces Progress on Cost Reduction Initiatives and Stay of Moratorium Proceedings

  10/26/2022

  ObsEva SA announced that the transition of the linzagolix program to Kissei Pharmaceutical Co., Ltd. is substantially complete following the assignment of substantially all clinical, manufacturing, and scientific contracts related to the development of linzagolix.

• 

  Clinical Catch-Up: January 10-14

  1/17/2022

  Heading into the middle of January, companies announced plenty of new clinical trial news. Here’s a look.

• CG Oncology Announces First Patient Dosed in Japan in Phase 3 Monotherapy Study of CG0070 in Non-Muscle-Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin

  12/20/2021

  CG Oncology, Inc. announced today it has triggered the first development milestone payment under its licensing agreement with Kissei Pharmaceutical Co., Ltd. for its oncology immunotherapy CG0070 for Japan South Korea, Taiwan and other Asian countries with the exception of China.

• VFMCRP announces approval for TAVNEOS® (avacopan) for the treatment of ANCA-associated vasculitis in Japan

  9/27/2021

  Vifor Fresenius Medical Care Renal Pharma announced that Japan’s Ministry of Health and Labor Welfare has granted its partner, Kissei Pharmaceutical Co., Ltd., marketing authorization approval for TAVNEOS® for the treatment of patients with granulomatosis with polyangiitis and microscopic polyangiitis, the two main types of ANCA-associated vasculitis, a rare and severe autoimmune renal disease with high unmet medical need.

• ChemoCentryx Announces Approval in Japan of TAVNEOS™ (Avacopan) for the Treatment of ANCA-Associated VasculitisApproved for use in Japan in patients with microscopic polyangiitis and granulomatosis with polyangiitis

  9/27/2021

  ChemoCentryx, Inc., announced that Kissei Pharmaceutical Co., Ltd. has received approval from the Japanese Ministry of Health, Labor, and Welfare to market TAVNEOS™ in Japan for the treatment of patients with microscopic polyangiitis and granulomatosis with polyangiitis, the two main forms of anti-neutrophil cytoplasmic autoantibody-associated vasculitis also known as ANCA-associated vasculitis or ANCA vasculitis.

• Inmagene and Kissei Enter into an Exclusive License Agreement for Fostamatinib in China

  8/5/2021

  Inmagene Biopharmaceuticals and Kissei Pharmaceutical Co., Ltd. announced that they have entered into an exclusive license agreement for the development and commercialization of fostamatinib in mainland China, Hong Kong and Macau.

• Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia

  9/23/2019

  Rigel Pharmaceuticals, Inc. announced that its collaboration partner, Kissei Pharmaceuticals Co., Ltd., has initiated a Phase 3 trial in Japan of fostamatinib disodium hexahydrate in adult patients with chronic immune thrombocytopenia.

• Rigel Pharmaceuticals Enters Collaboration and License Agreement with Kissei Pharmaceutical Co., Ltd. to Develop and Commercialize TAVALISSE™ (fostamatinib disodium hexahydrate) in Japan and other Asian Countries

  10/29/2018

  Kissei gains exclusive rights to fostamatinib in all current and potential indications in Japan and other Asian countries.

• Kissei Pharmaceutical Co., Ltd. To Market Avacopan In Japan For Vifor Fresenius Medical Care Renal Pharma

  6/9/2017

• ObsEva And Kissei Pharmaceutical Co., Ltd. Announce Global Agreement To Develop And Commercialize KLH-2109 For The Treatment Of Endometriosis

  11/20/2015

• Actavis and Kissei Pharmaceutical Co., Ltd. File Lawsuits Against Sandoz, Inc. and Hetero for Infringement of Rapaflo&#0174 Patent

  6/19/2013

• MediciNova, Inc. to Receive $2.5 Million Payment From Kissei Pharmaceutical Co., Ltd. to Expand Clinical Development of the MN-221 Program

  10/14/2011

• MediciNova, Inc. Announces Private Sale of Stock to Kissei Pharmaceutical Co., Ltd.

  9/27/2011

• SpePharm Sells Japanese Rights for Savene(R) to Kissei Pharmaceutical Co., Ltd.

  9/1/2011

• Protox Therapeutics Inc. Signs $75 Million License Agreement with Kissei Pharmaceutical Co., Ltd. for Commercialization of PRX302 in Japan for BPH and Prostate Disease

  4/30/2010

• Kissei Pharmaceutical Co., Ltd. Announces New Drug Application for Silodosin has been Filed with FDA

  2/13/2008

• Nuon Therapeutics Inc. Completes Licensing, Supply and Collaboration Agreement on Tranilast With Kissei Pharmaceutical Co., Ltd.

  7/23/2007

• Kissei Pharmaceutical Co., Ltd. and Eisai Company, Ltd. Sign a License Agreement to Develop and Commercialize Glufast(R), a Rapid-acting Insulin Secretagogue in 10 ASEAN Countries

  6/12/2007

• Kissei Pharmaceutical Co., Ltd. And Daiichi Pharmaceutical (JPN) Jointly Launch Urination Disorder Improving Drug

  5/12/2006

• Kissei Pharmaceutical Co., Ltd. To License KGA, Diabetes Drug Candidate, To GlaxoSmithKline

  4/10/2006